AbbVie’s (ABBV) Rinvoq Meets Goals in Crohn’s Disease Study Posted byZacks Equity Research December 7, 2021 Leave a comment on AbbVie’s (ABBV) Rinvoq Meets Goals in Crohn’s Disease Study AbbVie’s (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn’s Disease.